Jaroslaw P. Maciejewski

Dr. Jaroslaw P. Maciejewski


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2010 in Nature
Verified
Journal Article
Open access
PDF file
MKMyunggon Ko
Myunggon Ko
YHYun Huang
Yun Huang
AJAnna M. Jankowska
Anna M. Jankowska
UPUtz J. Pape
Utz J. Pape
MTMamta Tahiliani
Mamta Tahiliani
ARAnjana Rao
Anjana Rao
Enzymes of the TET family convert 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) in DNA. Mutations in the gene encoding TET2 are common in myeloid malignancies. These disease-associated mutations are now shown to compromise TET2 catalytic activity: bone-marrow samples from patients with TET2 mutations have low levels of 5-hmC in genomic DNA, and TET2 is required for normal haematopoietic differentiation. Measurement of genomic 5-hmC levels may prove valuable as a diagnostic tool in myeloid cancers. The TET family of enzymes convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA. Mutations in the gene encoding TET2 are frequently observed in myeloid malignancies. Here it is shown that these disease-associated mutations compromise TET2 catalytic activity; bone marrow samples from patients with TET2 mutations have low levels of 5hmC in genomic DNA, and TET2 is required for normal haematopoietic differentiation. Measurement of genomic 5hmC levels may prove valuable as a diagnostic tool in myeloid cancers. TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA1,2. The gene encoding TET2 resides at chromosome 4q24, in a region showing recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse myeloid malignancies3. Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML)4,5,6,7,8,9,10,11,12. We show here that TET2 mutations associated with myeloid malignancies compromise catalytic activity. Bone marrow samples from patients with TET2 mutations displayed uniformly low levels of 5hmC in genomic DNA compared to bone marrow samples from healthy controls. Moreover, small hairpin RNA (shRNA)-mediated depletion of Tet2 in mouse haematopoietic precursors skewed their differentiation towards monocyte/macrophage lineages in culture. There was no significant difference in DNA methylation between bone marrow samples from patients with high 5hmC versus healthy controls, but samples from patients with low 5hmC showed hypomethylation relative to controls at the majority of differentially methylated CpG sites. Our results demonstrate that Tet2 is important for normal myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours myeloid tumorigenesis. Measurement of 5hmC levels in myeloid malignancies may prove valuable as a diagnostic and prognostic tool, to tailor therapies and assess responses to anticancer drugs.

23 April 2015 in Cancer Cell
Verified
Journal Article
Closed access
CPChantana Polprasert
Chantana Polprasert
ISIsabell Schulze
Isabell Schulze
MSMikkael A. Sekeres
Mikkael A. Sekeres
HMHideki Makishima
Hideki Makishima
BPBartlomiej Przychodzen
Bartlomiej Przychodzen
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski

11 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
AJAndres Jerez
Andres Jerez
MCMichael J. Clemente
Michael J. Clemente
HMHideki Makishima
Hideki Makishima
HKHanna Koskela
Hanna Koskela
FLFrancis LeBlanc
Francis LeBlanc
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Chronic lymphoproliferative disorders of natural killer cells (CLPD-NKs) and T-cell large granular lymphocytic leukemias (T-LGLs) are clonal lymphoproliferations arising from either natural killer cells or cytotoxic T lymphocytes (CTLs). We have investigated for distribution and functional significance of mutations in 50 CLPD-NKs and 120 T-LGL patients by direct sequencing, allele-specific PCR, and microarray analysis. STAT3 gene mutations are present in both T and NK diseases: approximately one-third of patients with each type of disorder convey these mutations. Mutations were found in exons 21 and 20, encoding the Src homology 2 domain. Patients with mutations are characterized by symptomatic disease (75%), history of multiple treatments, and a specific pattern of STAT3 activation and gene deregulation, including increased expression of genes activated by STAT3. Many of these features are also found in patients with wild-type STAT3, indicating that other mechanisms of STAT3 activation can be operative in these chronic lymphoproliferative disorders. Treatment with STAT3 inhibitors, both in wild-type and mutant cases, resulted in accelerated apoptosis. STAT3 mutations are frequent in large granular lymphocytes suggesting a similar molecular dysregulation in malignant chronic expansions of NK and CTL origin. STAT3 mutations may distinguish truly malignant lymphoproliferations involving T and NK cells from reactive expansions.

19 December 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HMHideki Makishima
Hideki Makishima
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
KYKenichi Yoshida
Kenichi Yoshida
MSMikkael A Sekeres
Mikkael A Sekeres
TRTomas Radivoyevitch
Tomas Radivoyevitch
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski

5 February 2009 in Blood
Verified
Journal Article
Open access
PDF file
YJYing Jiang
Ying Jiang
ADAndrew Dunbar
Andrew Dunbar
LGLukasz P. Gondek
Lukasz P. Gondek
SMSanjay Mohan
Sanjay Mohan
MRManjot Rataul
Manjot Rataul
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML). As such, study of MDS/AML can provide insight into the mechanisms of neoplastic evolution. In 184 patients with MDS and AML, DNA methylation microarray and high-density single nucleotide polymorphism array (SNP-A) karyotyping were used to assess the relative contributions of aberrant DNA methylation and chromosomal deletions to tumor-suppressor gene (TSG) silencing during disease progression. Aberrant methylation was seen in every sample, on average affecting 91 of 1505 CpG loci in early MDS and 179 of 1505 loci after blast transformation (refractory anemia with excess blasts [RAEB]/AML). In contrast, chromosome aberrations were seen in 79% of early MDS samples and 90% of RAEB/AML samples, and were not as widely distributed over the genome. Analysis of the most frequently aberrantly methylated genes identified FZD9 as a candidate TSG on chromosome 7. In patients with chromosome deletion at the FZD9 locus, aberrant methylation of the remaining allele was associated with the poorest clinical outcome. These results indicate that aberrant methylation can cooperate with chromosome deletions to silence TSG. However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML.

5 April 2012 in Blood
Verified
Journal Article
Open access
PDF file
HMHideki Makishima
Hideki Makishima
VVValeria Visconte
Valeria Visconte
HSHirotoshi Sakaguchi
Hirotoshi Sakaguchi
AJAnna M. Jankowska
Anna M. Jankowska
SKSarah Abu Kar
Sarah Abu Kar
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Myelodysplastic syndromes (MDSs) are chronic and often progressive myeloid neoplasms associated with remarkable heterogeneity in the histomorphology and clinical course. Various somatic mutations are involved in the pathogenesis of MDS. Recently, mutations in a gene encoding a spliceosomal protein, SF3B1, were discovered in a distinct form of MDS with ring sideroblasts. Whole exome sequencing of 15 patients with myeloid neoplasms was performed, and somatic mutations in spliceosomal genes were identified. Sanger sequencing of 310 patients was performed to assess phenotype/genotype associations. To determine the functional effect of spliceosomal mutations, we evaluated pre-mRNA splicing profiles by RNA deep sequencing. We identified additional somatic mutations in spliceosomal genes, including SF3B1, U2AF1, and SRSF2. These mutations alter pre-mRNA splicing patterns. SF3B1 mutations are prevalent in low-risk MDS with ring sideroblasts, whereas U2AF1 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS. SF3B1 mutations are associated with a favorable prognosis, whereas U2AF1 and SRSF2 mutations are predictive for shorter survival. Mutations affecting spliceosomal genes that result in defective splicing are a new leukemogenic pathway. Spliceosomal genes are probably tumor suppressors, and their mutations may constitute diagnostic biomarkers that could potentially serve as therapeutic targets.